Bedaquiline resistance in patients with Xpert MTB/RIF Ultra-tested rifampicin-resistant tuberculosis in the Western Cape, South Africa: a prospective study
The Lancet Microbe·
- DOI
- 10.1016/j.lanmic.2025.101293
- PMID
- 41724179
- PMCID
- PMC13100955
- OpenAlex
- W7130517267
- Study type
- Cohort study
- Publisher
- Elsevier BV
- Article type
- journal-article
- Integrity
- current
Why this research matters now
Authors emphasize the necessity of prioritizing systematic monitoring for resistance to maintain effective treatment protocols. Elevated resistance levels in certain subgroups underscore the importance of updated diagnostic and therapeutic approaches.
Structured evidence summary
Research question
The investigation focused on quantifying the frequency of bedaquiline resistance within a defined group of individuals diagnosed with rifampicin-resistant tuberculosis.
Study design
Researchers conducted a prospective analysis of bacterial samples collected consecutively over a specific ten-month duration. Genotypic testing was applied alongside routine clinical processes to evaluate drug susceptibility profiles.
Population and setting
The study enrolled patients located in the Western Cape region of South Africa who underwent molecular screening for tuberculosis. Samples were obtained from sputum sediments and cultured isolates meeting specific resistance criteria.
Main findings
Analysis revealed varying rates of resistance depending on whether the infection was new or recurrent, with higher proportions found in later cases. The genomic assay demonstrated high concordance with standard laboratory methods for determining drug susceptibility status.
Public-health relevance
Authors emphasize the necessity of prioritizing systematic monitoring for resistance to maintain effective treatment protocols. Elevated resistance levels in certain subgroups underscore the importance of updated diagnostic and therapeutic approaches.
Important limitations
This summary is restricted to the information contained within the provided abstract and metadata, excluding the full manuscript. Detailed methodological constraints and potential biases cannot be fully assessed without access to the complete document.
GIDS interpretation
This record offers contextual data regarding antimicrobial resistance trends and diagnostic capabilities in a specific national setting. It serves as a reference point for understanding regional disease dynamics without implying real-time surveillance confirmation.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 11 auditable classifier relationships to diseases, places, topics, and study design.